{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:09:14Z","timestamp":1790665754543,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009841.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000}}],"reference-count":208,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009841.pub3","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T02:28:51Z","timestamp":1547000931000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Mica","family":"Skilton","sequence":"first","affiliation":[{"name":"University of Liverpool, Institute in the Park; c\/o Cochrane Cystic Fibrosis and Genetic Disorders Review Group; Eaton Road Liverpool UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashma","family":"Krishan","sequence":"additional","affiliation":[{"name":"University of Liverpool, Alder Hey Children's NHS Foundation Trust; Department of Women's and Children's Health; Eaton Road Liverpool Merseyside UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[{"name":"Stepping Hill Hopsital, Stockport NHS Foundation Trust; Poplar Grove Hazel Grove Stockport Cheshire UK SK2 7JE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian P","family":"Sinha","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Women's and Children's Health; Alder Hey Children's Foundation Trust Eaton Road Liverpool Merseyside UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W","family":"Southern","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Women's and Children's Health; Alder Hey Children's Foundation Trust Eaton Road Liverpool Merseyside UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"issue":"S32","key":"10.1002\/14651858.CD009841.pub3-BIB0001|cit1","first-page":"296","article-title":"Improvement in sweat chloride concentration by the CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation","volume":"44","author":"Accurso","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"21","key":"10.1002\/14651858.CD009841.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD009841.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1-33 online","DOI":"10.1056\/NEJMoa0909825","article-title":"Online supplementary appendix to \"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation\" [online]","volume":"363","author":"Accurso","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD009841.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1991-2003 onlin","DOI":"10.1056\/NEJMoa0909825","article-title":"Online supplementary material (disclosure forms) to \"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation\" [online]","volume":"363","author":"Accurso","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD009841.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1-121 online","DOI":"10.1056\/NEJMoa0909825","article-title":"Online supplementary material (protocol) to \"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation\" [online]","volume":"363","author":"Accurso","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(09)60101-6","article-title":"Final results of a 14-and 28-day study of VX-770 in subjects with CF","volume":"8 Suppl 2","author":"Accurso","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S1","key":"10.1002\/14651858.CD009841.pub3-BIB0007|cit7","first-page":"295","article-title":"Interim results of phase 2a study of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D","volume":"43","author":"Accurso","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"139-147 online","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Online Data Supplement to \"Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data\"","volume":"13","author":"Accurso","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/13543784.2011.554823","article-title":"Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. New England Journal of Medicine 2010;363(21):1991-2003","volume":"20","author":"Antoniu","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"S32","key":"10.1002\/14651858.CD009841.pub3-BIB0011|cit11","first-page":"287","article-title":"Effect of VX-770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D-CFTR mutation","volume":"44","author":"Boyle","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"S32","key":"10.1002\/14651858.CD009841.pub3-BIB0012|cit12","first-page":"288","article-title":"NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator","volume":"44","author":"Clancy","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0013|cit13","unstructured":"Donaldson S Accurso F Rowe S Clancy J Boyle M Dunitz J Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation European Respiratory Society Annual Congress; 2010 Sep 18-22; Barcelona, Spain 2010 34s"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD009841.pub3-BIB0014|cit14","first-page":"A2336","article-title":"Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D-CFTR Mutation Treated With VX-770, An Investigational Oral Potentiator Of CFTR","volume":"181","author":"Konstan","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(10)60075-6","article-title":"Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo","volume":"9 Suppl 1","author":"Rowe","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"e66955","DOI":"10.1371\/journal.pone.0066955","article-title":"Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation","volume":"8","author":"Rowe","year":"2013","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0017|cit17","first-page":"319","article-title":"Corresponding effects of VW-770 on NPD in vivo & human bronchial epithelial (HBE) cells in vitro","volume":"45 Suppl 33","author":"Rowe","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"S31","key":"10.1002\/14651858.CD009841.pub3-BIB0018|cit18","first-page":"314.","article-title":"Relationship of VX-770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX-770","volume":"43","author":"Goor","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0019|cit19","first-page":"284","article-title":"VX-770 in subjects with CF and homozygous for the F508del-CFTR mutation","volume":"46 Suppl 34","author":"Flume","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60080-5","article-title":"VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"10 Suppl 1","author":"Flume","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"718-24 online","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"issue":"S34","key":"10.1002\/14651858.CD009841.pub3-BIB0023|cit23","first-page":"283","article-title":"VX-770 in subjects 6 to 11 years with cystic fibrosis and the G551D-CFTR mutation","volume":"46","author":"Aherns","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10620-015-3834-2","article-title":"Nutritional status improved in cystic fibrosis patients with the G551D mutation","volume":"61","author":"Borowitz","year":"2016","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1569-1993(12)60041-1","article-title":"Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation","volume":"11 Suppl 1","author":"Borowitz","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S35","key":"10.1002\/14651858.CD009841.pub3-BIB0026|cit26","first-page":"298","article-title":"Nutritional status measures among persons with CF carrying the G551D-CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials","volume":"47","author":"Borowitz","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD009841.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009841.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1219-1225 onlin","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Online Supplement to \"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation\" [online]","volume":"187","author":"Davies","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1569-1993(12)60043-5","article-title":"Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation","volume":"11 Suppl 1","author":"Davies","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0030|cit30","first-page":"298","article-title":"Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted","volume":"48 Suppl 36","author":"Elborn","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0031|cit31","first-page":"1073s","article-title":"Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis","volume":"42","author":"Elborn","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S1569-1993(13)60200-3","article-title":"Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor","volume":"12 Suppl 1","author":"Flume","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD009841.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ppul.23173","article-title":"Efficacy response in CF patients treated with ivacaftor: post-hoc analysis","volume":"50","author":"Konstan","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1569-1993(13)60195-2","article-title":"Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis","volume":"12 Suppl 1","author":"Plant","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0036|cit36","first-page":"297","article-title":"Patient-reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation","volume":"47 Suppl 35","author":"Quittner","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S67, Abstract n","DOI":"10.1016\/S1569-1993(12)60212-4","article-title":"Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"Quittner","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S1569-1993(16)30436-2","article-title":"Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D-CTFR mutation: data from the ENVISION study","volume":"15 Suppl","author":"Stalvey","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0039|cit39","first-page":"402","article-title":"Ivacaftor improves linear growth in G551D cystic fibrosis children: results of a multicenter, placebo-controlled study","volume":"50 Suppl 41","author":"Stalvey","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"e20162522","DOI":"10.1542\/peds.2016-2522","article-title":"Growth in prepubertal children with cystic fibrosis treated with ivacaftor","volume":"139","author":"Stalvey","year":"2017","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0042|cit41","doi-asserted-by":"crossref","unstructured":"Moss R Study of ivacaftor in subjects with cystic fibrosis who have the R117H-CFTR mutation (KONDUCT) Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014) 2014","DOI":"10.1016\/S1569-1993(14)60137-5"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0041|cit42","first-page":"221","article-title":"Effects of ivacaftor in CF patients with R117H-CFTR","volume":"49 Suppl 38","author":"Moss","year":"2014","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S1569-1993(14)60137-5","article-title":"Ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study","volume":"13 Suppl 2","author":"Moss","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10620-015-3834-2","article-title":"Nutritional status improved in cystic fibrosis patients with the G551D mutation","volume":"61","author":"Borowitz","year":"2016","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1569-1993(12)60041-1","article-title":"Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation","volume":"11 Suppl 1","author":"Borowitz","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0047|cit47","first-page":"298","article-title":"Nutritional status measures among persons with CF carrying the G551D-CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials","volume":"47 Suppl 35","author":"Borowitz","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0048|cit48","first-page":"298","article-title":"Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted","volume":"48 Suppl 36","author":"Elborn","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0049|cit49","first-page":"1073s","article-title":"Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis","volume":"42","author":"Elborn","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S1569-1993(13)60200-3","article-title":"Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor","volume":"12 Suppl 1","author":"Flume","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcf.2017.06.002","article-title":"Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor","volume":"17","author":"Flume","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1569-1993(12)60213-6","article-title":"Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation","volume":"11 Suppl 1","author":"Griese","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD009841.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ppul.23173","article-title":"Efficacy response in CF patients treated with ivacaftor: post-hoc analysis","volume":"50","author":"Konstan","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1569-1993(12)60042-3","article-title":"Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation","volume":"11 Suppl 1","author":"McKone","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(16)30208-9","article-title":"Improved rate of decline in percent predicted FEV1 (ppfev1) is not associated with acute improvement in ppfev1 in patients with cystic fibrosis (CF) treated with ivacaftor","volume":"15 Suppl 1","author":"McKone","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1569-1993(13)60195-2","article-title":"Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis","volume":"12 Suppl 1","author":"Plant","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0058|cit58","first-page":"297","article-title":"Patient-reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation","volume":"47 Suppl 35","author":"Quittner","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12955-015-0293-6","article-title":"Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial","volume":"13","author":"Quittner","year":"2015","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1569-1993(12)60212-4","article-title":"Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation","volume":"11 Suppl 1","author":"Quittner","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S34","key":"10.1002\/14651858.CD009841.pub3-BIB0061|cit61","first-page":"286","article-title":"Efficacy and safety of VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation","volume":"46","author":"Ramsey","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"18","key":"10.1002\/14651858.CD009841.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD009841.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1663-1672 onlin","DOI":"10.1056\/NEJMoa1105185","article-title":"Online Supplementary Appendix to \"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation\" [online]","volume":"365","author":"Ramsey","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0064|cit64","first-page":"298","article-title":"Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D-CFTR mutation","volume":"48 Suppl 36","author":"Seliger","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12955-016-0465-z","article-title":"Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis","volume":"14","author":"Solem","year":"2016","journal-title":"Health and Quality of Life Outcomes"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"A535","DOI":"10.1016\/j.jval.2014.08.1707","article-title":"Impact of pulmonary exacerbations on EQ-5D measures in patients with cystic fibrosis","volume":"17","author":"Solem","year":"2014","journal-title":"Value in Health"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"A178","DOI":"10.1016\/j.jval.2014.03.1038","article-title":"Responsiveness of the EQ-5D index and visual analog scale to changes in lung function in patients with cystic fibrosis","volume":"17","author":"Solem","year":"2014","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1569-1993(13)60198-8","article-title":"Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis","volume":"12 Suppl 1","author":"Accurso","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009841.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1569-1993(18)30122-X","article-title":"GLPG2222 in subjects with cystic fibrosis and the F508del\/Class III mutation on stable treatment with ivacaftor: results from a phase II study (ALBATROSS)","volume":"17","author":"Bell","year":"2018","journal-title":"Journal of cystic fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD009841.pub3-BIB0070|cit70","first-page":"249","article-title":"Results from a phase ii study - albatross - evaluation of glpg2222 in subjects with cf and the f508del\/class iii mutation on stable treatment with ivacaftor","volume":"53","author":"Bell","year":"2018","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1569-1993(14)60020-5","article-title":"The effect of ivacaftor treatment on lung ventilation defects, as measured by hyperpolarized helium-3 MRI, on patients with cystic fibrosis and a G551D-CFTR mutation","volume":"13 Suppl 2","author":"Altes","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcf.2016.12.004","article-title":"Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis","volume":"16","author":"Altes","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1569-1993(12)60215-X","article-title":"Hyperpolarized Gas MRI of ivacaftor therapy in subjects with cystic fibrosis who have the G551D-CFTR mutation","volume":"11 Suppl 1","author":"Altes","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0074|cit74","first-page":"291","article-title":"Hyperpolarized gas MRI of ivacaftor therapy in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"47 Suppl 35","author":"Altes","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"S34","key":"10.1002\/14651858.CD009841.pub3-BIB0075|cit75","first-page":"284","article-title":"Hyperpolarized helium-3 magnetic resonance imaging of CFTR potentiator therapy in subjects with cystic fibrosis and the G551D mutation","volume":"46","author":"Altes","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0077|cit77","first-page":"295","article-title":"Correlation between individual clinical responses and forskolin-induced swelling of paired intestinal organoids upon CFTR modulator treatment","volume":"52 Suppl 47","author":"Berkers","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0078|cit78","first-page":"278","article-title":"Nasal application of glycerol in DF508 cystic fibrosis patients","volume":"26 Suppl 17","author":"Chadwick","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0080|cit80","first-page":"298","article-title":"A phase II, randomized, placebo-controlled, clinical trial of four doses of VX-809 in CF patients homozygous for the F508del CFTR mutation","volume":"45 Suppl 33","author":"Clancy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0081|cit81","first-page":"283, Abstract n","article-title":"Variability of nasal potential difference measurements in clinical testing of CFTR modulators [abstract]","volume":"46 Suppl 34","author":"Clancy","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(10)60074-4","article-title":"Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"9 Suppl 1","author":"Clancy","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1569-1993(13)60198-8","article-title":"Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis","volume":"12 Suppl 1","author":"Accurso","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"8","key":"10.1002\/14651858.CD009841.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S2213-2600(13)70182-6","article-title":"Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial","volume":"1","author":"Davies","year":"2013","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0085|cit85","first-page":"311","article-title":"Lung clearance index to evaluate the effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease","volume":"47 Suppl 35","author":"Davies","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S1569-1993(12)60049-6","article-title":"Effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease: a comparison of lung clearance index (LCI) vs. spirometry","volume":"11 Suppl 1","author":"Davies","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0087|cit87","first-page":"298","article-title":"Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted","volume":"48 Suppl 36","author":"Elborn","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0088|cit88","first-page":"282","article-title":"Lung clearance index as an outcome measure in cystic fibrosis clinical trials","volume":"46 Suppl 34","author":"Ratjen","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0089|cit89","first-page":"A2819","article-title":"Lung clearance index as an endpoint in a multicenter randomized control trial of ivacaftor in subjects with cystic fibrosis who have mild lung disease","volume":"185","author":"Ratjen","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"The Lancet. Respiratory medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1569-1993(15)30056-4","article-title":"Effect of ivacaftor on wellness, quality of life and cognitive function in adults with cystic fibrosis and G551D mutation","volume":"14 Suppl 1","author":"Button","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0092|cit92","first-page":"437","article-title":"Ivacaftor improves wellness, quality of life and cognitive function in G551D cystic fibrosis","volume":"50 Suppl 41","author":"Button","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"15","key":"10.1002\/14651858.CD009841.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1042\/CS20170995","article-title":"Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment","volume":"131","author":"Edgeworth","year":"2017","journal-title":"Clinical Science"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"PA2047","DOI":"10.1183\/13993003.congress2015.PA2047","article-title":"Exercise improvements in ivacaftor treated G551D cystic fibrosis patients are not solely related to FEV1 and sweat changes","volume":"46 Suppl","author":"Edgeworth","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(15)30084-9","article-title":"Ivacaftor improves exercise capacity in patients with G551D CF gene mutations","volume":"14 Suppl 1","author":"Edgeworth","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1569-1993(17)30410-1","article-title":"Sweat chloride response does not reliably correlate with clinical parameters: a placebo controlled crossover trial of ivacaftor in G551D CF patients","volume":"16 Suppl 1","author":"Keating","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S1569-1993(15)30162-4","article-title":"Ivacaftor and its effects on body composition in adults with G551D related cystic fibrosis","volume":"14 Suppl 1","author":"Tierney","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S1569-1993(15)30149-1","article-title":"Patient reported adherence to ivacaftor","volume":"14 Suppl 1","author":"Williams","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S1569-1993(17)30437-X","article-title":"The effect of ivacaftor CFTR gene-potentiating therapy on cytokine levels in CF patients with the G551D mutation","volume":"16 Suppl 1","author":"Wilson","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009841.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1569-1993(18)30297-2","article-title":"Treatment with ivacaftor in CF patients with the G551D mutation is associated with improvement in cognition","volume":"17","author":"Wilson","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0101|cit101","first-page":"236","article-title":"Ivacaftor CFTR gene-potentiating therapy reduces inflammatory cytokine levels in CF patients with G551D mutation","volume":"52 Suppl 47","author":"Wilson","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0102|cit102","unstructured":"EudraCT Number: 2014-000817-30 Comparing the effect of curcumin and genistein to treatment with Ivacaftor in CF patients with a class III mutation clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000817-30\/NL"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0103|cit103","unstructured":"EudraCT Number: 2016-001440-18 Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001440-18\/NL"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0104|cit104","unstructured":"EudraCT Number: 2016-001619-19 Genistein as an add-on treatment for CF? clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001619-19\/NL"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0105|cit105","unstructured":"EudraCT Number: 2016-001785-29 Combined effect of CFTR modifiers and intensive antibiotic treatment clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001785-29\/IE"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009841.pub3-BIB0106|cit106","first-page":"S42","article-title":"GLPG2222 in subjects with cystic fibrosis homozygous for F508del: results from a phase II study (FLAMINGO)","volume":"17","author":"Ent","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD009841.pub3-BIB0107|cit107","first-page":"250","article-title":"Glpg2222 in CF subjects homozygous for f508del: results from a phase ii study (Flamingo)","volume":"53","author":"Ent","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009841.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(18)30251-0","article-title":"Safety, pharmacokinetics and pharmacodynamics of the CFTR corrector FDL169","volume":"17","author":"Horsley","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S2","key":"10.1002\/14651858.CD009841.pub3-BIB0109|cit109","first-page":"252","article-title":"Novel CFTR corrector FDL169: safety, pharmacokinetics and pharmacodynamics","volume":"53","author":"Horsley","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","article-title":"Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting","volume":"17","author":"Hubert","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1569-1993(13)60205-2","article-title":"The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease","volume":"12 Suppl 1","author":"Ajayi","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(16)30133-3","article-title":"Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range","volume":"15 Suppl 1","author":"Davies","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(16)30132-1","article-title":"Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin","volume":"15 Suppl 1","author":"Boeck","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub3-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S1569-1993(16)30502-1","article-title":"Natural history of patients with cystic fibrosis carrying nonsense mutations: an analysis of placebo-treated patients from the 009 study","volume":"15 Suppl 1","author":"Kerem","year":"2016","journal-title":"Journal of cystic fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0116|cit116","first-page":"312","article-title":"Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease","volume":"47 Suppl 35","author":"Kerem","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1569-1993(11)60084-2","article-title":"Phase 3 study of ataluren (PTC124\u00ae) in nonsense mutation cystic fibrosis (nmCF): baseline data","volume":"10 Suppl 1","author":"Kerem","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0118|cit118","first-page":"314","article-title":"Phase 3 study of Ataluren (PTC124\u00ae) in nonsense mutation cystic fibrosis (NMCF): demographic & other baseline data","volume":"45 Suppl 33","author":"Kerem","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S1569-1993(14)60230-7","article-title":"The effect of Pseusdomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis","volume":"13 Suppl 2","author":"Kerem","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S1569-1993(13)60044-2","article-title":"Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF)","volume":"12 Suppl 1","author":"Kerem","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0121|cit121","first-page":"295","article-title":"Pretreatment data from phase 3 study of Ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis","volume":"46 Suppl 34","author":"Konstan","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0122|cit122","first-page":"298","article-title":"Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis","volume":"48 Suppl 36","author":"Konstan","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0123|cit123","first-page":"290","article-title":"Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF)","volume":"47 Suppl 35","author":"Rowe","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0124|cit124","first-page":"279","article-title":"The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis","volume":"48 Suppl 36","author":"Rowe","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(14)60004-7","article-title":"The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non-G551D-CFTR gating mutation, the KONNECTION study","volume":"13 Suppl 2","author":"Boeck","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0126|cit126","first-page":"292","article-title":"Ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non-G551D-CFTR gating mutation: phase 3, part 1 results","volume":"48 Suppl 36","author":"Boeck","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ppul.10043","article-title":"Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis","volume":"33","author":"Ahrens","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"S17","key":"10.1002\/14651858.CD009841.pub3-BIB0128|cit128","first-page":"276","article-title":"Safety of a phase I double-blind placebo-controlled dose escalation trial of oral CPX in adult CF patients","volume":"26","author":"Aitken","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ppul.10041","article-title":"A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis","volume":"33","author":"McCarty","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0130|cit130","first-page":"276","article-title":"Multicenter phase I trial of CPX in adults patients with mild CF: results of nasal potential difference measurements","volume":"Suppl 17","author":"McCarty","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0131|cit131","first-page":"292","article-title":"Ivacaftor response is not predicted by signs of residual CFTR function","volume":"50 Suppl 41","author":"McGarry","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD009841.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ppul.23659","article-title":"In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: n-of-1 studies","volume":"52","author":"McGarry","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0133|cit133","first-page":"298","article-title":"Sweat chloride as an outcome measure in n-of-one CF drug testing","volume":"50 Suppl 41","author":"Nielson","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0134|cit134","unstructured":"NCT01549314 Cystic Fibrosis Related Bone Disease: the Role of CFTR clinicaltrials.gov\/ct2\/show\/NCT01549314"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0135|cit135","unstructured":"NCT01685801 Pilot study testing the effect of ivacaftor on lung function in subjects with cystic fibrosis and residual CFTR function clinicaltrials.gov\/ct2\/show\/NCT01685801"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0136|cit136","unstructured":"NCT01784419 Short term effects of ivacaftor in non-G551D cystic fibrosis patients clinicaltrials.gov\/ct2\/show\/NCT01784419"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0137|cit137","unstructured":"NCT01863238 An ocular safety study of ivacaftor-treated pediatric patients 11 years of age or younger with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01863238"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0138|cit138","unstructured":"NCT01946412 Roll-over study of ivacaftor in cystic fibrosis pediatric subjects with a CF transmembrane conductance regulator gene (CFTR) gating mutation clinicaltrials.gov\/ct2\/show\/NCT01946412"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0139|cit139","unstructured":"NCT02039986 Ivacaftor (Kalydeco) and insulin in cystic fibrosis (CF) clinicaltrials.gov\/ct2\/show\/NCT02039986"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0140|cit140","unstructured":"NCT02141464 Energy balance and weight gain with ivacaftor treatment clinicaltrials.gov\/ct2\/show\/NCT02141464"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0141|cit141","unstructured":"NCT02310789 Does ivacaftor alter wild type CFTR-open probability in the sweat gland secretory coil? clinicaltrials.gov\/ct2\/show\/NCT02310789"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0142|cit142","unstructured":"NCT02311140 Effects of Kalydeco on upper airway and paranasal sinus inflammation measured by nasal lavage and on symptoms (KPNSI) clinicaltrials.gov\/ct2\/show\/NCT02311140"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0143|cit143","unstructured":"NCT02323100 Glycerol phenylbutyrate corrector therapy for CF (Cystic Fibrosis) clinicaltrials.gov\/show\/nct02323100"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0144|cit144","unstructured":"NCT02443688 A phase 2 study to evaluate the efficacy, safety, and tolerability of CTX-4430 in adult CF patients clinicaltrials.gov\/ct2\/show\/NCT02443688"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0145|cit145","unstructured":"NCT02445053 Observational study of outcomes in cystic fibrosis patients with selected gating mutations on a CFTR allele (The VOCAL Study) (VOCAL) clinicaltrials.gov\/ct2\/show\/NCT02445053"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0146|cit146","unstructured":"NCT02690519 Study of GLPG1837 in subjects with cystic fibrosis (S1251N mutation) (SAPHIRA2) clinicaltrials.gov\/ct2\/show\/NCT02690519"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0147|cit147","unstructured":"NCT02707562 Study of GLPG1837 in subjects with cystic fibrosis (G551D Mutation) (SAPHIRA1) clinicaltrials.gov\/ct2\/show\/NCT02707562"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0148|cit148","unstructured":"NCT02709109 A study to evaluate the safety and efficacy of VX-371 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation clinicaltrials.gov\/ct2\/show\/NCT02709109"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0149|cit149","unstructured":"NCT02718495 Study assessing PTI-428 safety, tolerability, and pharmacokinetics in subjects with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT02718495"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0150|cit150","unstructured":"NCT02722057 A study to confirm the long-term safety and effectiveness of Kalydeco in patients with cystic fibrosis who have an R117H-CFTR mutation, including pediatric patients clinicaltrials.gov\/ct2\/show\/NCT02722057"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0151|cit151","unstructured":"NCT02724527 Study of cavosonstat (N91115) in CF patients who are heterozygous for F508del-CFTR and a gating mutation and being treated with ivacaftor (SNO-7) clinicaltrials.gov\/ct2\/show\/NCT02724527"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0152|cit152","unstructured":"NCT02742519 A study to evaluate efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 3 through 5 years who have a specified CFTR gating mutation clinicaltrials.gov\/ct2\/show\/NCT02742519"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0153|cit153","unstructured":"NCT02759562 Effect of andecaliximab on FEV1 in adults with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT02759562"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0154|cit154","unstructured":"NCT02934698 An efficacy and safety study of ivacaftor in patients with cystic fibrosis and two splicing mutations clinicaltrials.gov\/ct2\/show\/NCT02934698"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0155|cit155","unstructured":"NCT03068312 A study to evaluate efficacy of ivacaftor in subjects with cystic fibrosis who have a 3849 + 10KB C\u2192T or D1152H CFTR mutation clinicaltrials.gov\/ct2\/show\/NCT03068312"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0156|cit156","unstructured":"NCT03256799 Evaluation of ivacaftor in patients using ataluren for nonsense mutations clinicaltrials.gov\/ct2\/show\/NCT03256799"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0157|cit157","unstructured":"NCT03256968 PTC study to evaluate ataluren in combination with ivacaftor clinicaltrials.gov\/ct2\/show\/NCT03256968"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0158|cit158","unstructured":"NCT03258424 Study assessing PTI-428 safety, tolerability, and pharmacokinetics in subjects with cystic fibrosis on KALYDECO\u00ae as background therapy clinicaltrials.gov\/ct2\/show\/NCT03258424"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0159|cit159","unstructured":"NCT03277196 A phase 3, 2-arm, open-label study to evaluate the safety and pharmacodynamics of long-term ivacaftor treatment in subjects with cystic fibrosis who are less than 24 months of age at treatment initiation and have an approved ivacaftor-responsive mutation clinicaltrials.gov\/ct2\/show\/NCT03277196"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0160|cit160","unstructured":"NCT03390985 Canadian observation trial in CF patients undergoing treatment with ivacaftor (G551D) clinicaltrials.gov\/ct2\/show\/NCT03390985"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0161|cit161","unstructured":"NCT03474042 GLPG2737 on top of Orkambi in subjects with cystic fibrosis (PELICAN) clinicaltrials.gov\/ct2\/show\/NCT03474042"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0162|cit162","unstructured":"NCT03652090 Evaluation of the Primary Human Nasal Epithelial Cell Culture Model in the Context of Personalized Therapy in Cystic Fibrosis clinicaltrials.gov\/ct2\/show\/NCT03652090"},{"issue":"11","key":"10.1002\/14651858.CD009841.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"The Lancet. Respiratory medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0164|cit164","first-page":"263","article-title":"Effects of gentamicin on ion transport, MRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study","volume":"34 Suppl 24","author":"Pradal","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD009841.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S1569-1993(17)30276-X","article-title":"Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study","volume":"16","author":"Derichs","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Supplement 47","key":"10.1002\/14651858.CD009841.pub3-BIB0166|cit166","first-page":"307","article-title":"Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: safety data from the rio-CF study","volume":"52","author":"Taylor-Cousar","year":"2017","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009841.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1569-1993(18)30325-4","article-title":"Riociguat for the treatment of adult Phe508del homozygous cystic fibrosis: efficacy data from the Phase II Rio-CF study","volume":"17","author":"Taylor-Cousar","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0168|cit168","unstructured":"Romano L Casciaro R Vanini P Zegarra-Moran O Negro I Minuto N Reduction of sweat ion concentrations following topical application of gentamicin in CF patients carrying nonsense mutations Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P11"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0169|cit169","first-page":"250","article-title":"Effects of topical applications of gentamicin on sweat test in CF patients carrying nonsense-mutations","volume":"30 Suppl 20","author":"Romano","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/ajrccm.157.2.9706088","article-title":"A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function","volume":"157","author":"Rubenstein","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0171|cit171","first-page":"272","article-title":"A randomized, double blind, placebo-controlled trial of sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function","volume":"24 Suppl 14","author":"Rubenstein","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0172|cit172","first-page":"294","article-title":"A pilot trial of the combination of phenylbutyrate and genistein","volume":"41 Suppl 29","author":"Rubenstein","year":"2006","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S1569-1993(15)30373-8","article-title":"Prevalance of cataracts in a population of cystic fibrosis patients homozygous for the F508del mutation","volume":"14 Suppl 1","author":"Seliger","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"10","key":"10.1002\/14651858.CD009841.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0175|cit175","unstructured":"NCT03085485 The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor clinicaltrials.gov\/ct2\/show\/NCT03085485"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0176|cit176","first-page":"244","article-title":"Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: a double-blind placebo controlled trial","volume":"30 Suppl 20","author":"Wilschanski","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD009841.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"A582","DOI":"10.1016\/S0016-5085(03)82949-9","article-title":"Restoration of CFTR function by gentamicin in cystic fibrosis patients carrying stop mutations: a double blind placebo controlled trial","volume":"124","author":"Wilschanski","year":"2003","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD009841.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0179|cit179","first-page":"294","article-title":"PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis","volume":"43 Suppl 31","author":"Kerem","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0180|cit180","first-page":"313","article-title":"Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124","volume":"43 Suppl 31","author":"Sermet-Gaudelus","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(08)60084-3","article-title":"PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF","volume":"7 Suppl 2","author":"Sermet-Gaudelus","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(08)60085-5","article-title":"PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense -mutation-mediated CF","volume":"7 Suppl 2","author":"Wilschanski","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.2002.0639","article-title":"Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate","volume":"6","author":"Zeitlin","year":"2002","journal-title":"Molecular Therapy"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD009841.pub3-BIB0184|cit184","first-page":"A7789","article-title":"QBW251 is a safe and efficacious CFTR potentiator for patients with cystic fibrosis","volume":"193","author":"Kazani","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0185|cit185","unstructured":"NCT02190604 Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients. clinicaltrials.gov\/ct2\/show\/NCT02190604"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0186|cit186","first-page":"277","article-title":"CTP-656 multiple dose pharmacokinetic profile continues to support a once-daily potentiator for cystic fibrosis patients with gating mutations","volume":"51 Suppl 45","author":"Uttamsingh","year":"2016","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.tips.2007.05.004","article-title":"Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis","volume":"28","author":"Amaral","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub3-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012040.pub2","article-title":"Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.","author":"Aslam","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD009841.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Human Mutation"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0190|cit190","unstructured":"Hospital for Sick Children in Toronto Cystic Fibrosis Mutation Database www.genet.sickkids.on.ca\/StatisticsPage.html"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0191|cit191","unstructured":"Deeks J Higgins J Altman D Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3476(98)70441-X","article-title":"Comparison of the clinical manifestations of cystic fibrosis in black and white patients","volume":"132","author":"Hamosh","year":"1998","journal-title":"Journal of Pediatrics"},{"issue":"7414","key":"10.1002\/14651858.CD009841.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0194|cit194","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0195|cit195","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0196|cit196","unstructured":"NCT01707290 Rollover study of ivacaftor in subjects with cystic fibrosis and a non G551D CFTR mutation (KONTINUE) clinicaltrials.gov\/ct2\/show\/NCT01707290"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ddmec.2004.08.012","article-title":"Cystic fibrosis: disease mechanisms and therapeutic targets","volume":"1","author":"McKone","year":"2004","journal-title":"Drug Discovery Today: Disease Mechanisms"},{"issue":"6","key":"10.1002\/14651858.CD009841.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"4922","key":"10.1002\/14651858.CD009841.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"5","key":"10.1002\/14651858.CD009841.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1469-1809.2003.00028.x","article-title":"The phenotypic consequences of CFTR mutations","volume":"67","author":"Rowntree","year":"2003","journal-title":"Annals of Human Genetics"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/adc.76.3.278","article-title":"Delta F508 in cystic fibrosis: Willing but not able","volume":"76","author":"Southern","year":"1997","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000102068","article-title":"Cystic fibrosis and formes frustes of CFTR-related disease","volume":"74","author":"Southern","year":"2007","journal-title":"Respiration: International Review of Thoracic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD009841.pub3-BIB0203|cit203","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010966.pub2","article-title":"Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis","author":"Southern","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009841.pub3-BIB0204|cit204","unstructured":"UK CF Trust Cystic fibrosis: our focus www.cysticfibrosis.org.uk\/media\/598466\/annual-data-report-2013-jul14.pdf"},{"issue":"44","key":"10.1002\/14651858.CD009841.pub3-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.","volume":"106","author":"Goor","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"18","key":"10.1002\/14651858.CD009841.pub3-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18180","article-title":"Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis","volume":"18","author":"Whiting","year":"2014","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"5","key":"10.1002\/14651858.CD009841.pub3-BIB0207|cit207","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009841","article-title":"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis","author":"Patel","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub3-BIB0208|cit208","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009841.pub2","article-title":"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis","author":"Patel","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009841.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:24:15Z","timestamp":1686187455000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009841.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":208,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009841.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]}}}